

<b>Supplementary Table 2: Summary of patients receiving immunotherapies</b>		
<b>Non-checkpoint inhibitor immunotherapies</b>	<b># of UP patients</b>	<b># of KP patients</b>
Anti-CD137 (4-1BB)	2	3
TLR4 agonist (GLA)	0	2
IFNbeta injection	0	1
IL-12 DNA electroporation	2	0
Anti-CD56	2	0
Autologous T cell therapy	1	0
IL-2	1	0
<b>Checkpoint inhibitor immunotherapies</b>	<b># of UP patients</b>	<b># of KP patients</b>
Anti-PD-L1 (avelumab)	0	2
Anti-CTLA4 and anti-PD-1 (ipilimumab and nivolumab)	0	1
Anti-PD-1 (nivolumab/pembrolizumab)	0	3
<b>Other therapy (excluding radiation, surgery, chemo)</b>	<b># of UP patients</b>	<b># of KP patients</b>
Tyrosine kinase inhibitor (votrient)	1	1
Somatostatin analog (sandostatin)	4	0
topoisomerase inhibitors (Topotecan and irinotecan)	3	0